Drug interaction potential of 2-((3,4- dichlorophenethyl)(propyl)amino)-1- (pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent

Drug Metabolism and Disposition

Volumn 37, Issue 2, 2009, Pages 375-385

  Monostory, Katalin ^a,g   Pascussi, Jean Marc ^b   Szabó, Pál ^a   Temesvári, Manna ^a   Kohalmy, Krisztina ^a   Acimovic, Jure ^c   Kocjan, Darko ^d   Kuzman, Drago ^d   Wilzewski, Britta ^e   Bernhardt, Rita ^e   Kóbori, Lászió ^f   Rozman, Damjana ^c  

^a CHEMICAL RESEARCH CENTER   (Hungary)

^b INSERM   (France)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

^d Lek dd   (Slovenia)

^e SAARLAND UNIVERSITY   (Germany)

^f SEMMELWEIS UNIVERSITY   (Hungary)

^g NONE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(3,4 DICHLOROPHENETHYL)(PROPYL)AMINO] 1 (PYRIDIN 3 YL)ETHANOL; ATORVASTATIN; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LK 935; PYRIDINE DERIVATIVE; RIFAMPICIN; ROSUVASTATIN; STEROL 14ALPHA DEMETHYLASE; UNCLASSIFIED DRUG;

ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL; MYOPATHY; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ANTICHOLESTEREMIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHOLESTEROL; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FLUOROBENZENES; HEPATOCYTES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRIMIDINES; PYRROLES; SULFONAMIDES;

EID: 59649121381     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.023887     Document Type: Article

References (41)

1. Alsheikh-Ali AA, Maddukuri PV, Han H, and Karas RH (2007) Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer. J Am Coll Cardiol 50:409-418.
2. Armitage J (2007) The safety of statins in clinical practice. Lancet 370:1781-1790.
3. Bayliss KM and Skett P (1996) Isolation and culture of human hepatocytes, in Human Cell Culture Protocols (Jones GE ed) pp 369-390, Humana Press, Totowa, NJ.
4. Bays HE, Neff D, Tomassini JE, and Tershakovec AM (2008) Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 6:447-470.
5. Beaird SL (2000) HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc 40:637-644.
6. Bourrié M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
7. Buhaescu I and Izzedine H (2007) Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 40:575-584.
8. Chen Y, Ferguson SS, Negishi M, and Goldstein JA (2003) Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol 64:316 -324.
9. Debeljak N, Fink M, and Rozman D (2003) Many facets of mammalian lanosterol 14α-demethylase from the evolutionarily conserved cytochrome P450 family CYP51. Arch Biochem Biophys 409:159-171.
10. El-Sankary W, Gibson GG, Ayrton A, and Plant N (2001) Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 29:1499 -1504.
11. Ferrini JB, Ourlin JC, Pichard L, Fabre G, and Maurel P (1998) Human hepatocyte culture, in Cytochrome P450 Protocols (Phillips IR and Shephard EA eds) pp 341-352, Humana Press, Totowa, NJ.
12. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, and Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
13. Heyn H, White RB, and Stevens JC (1996) Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 24:948 -954.
14. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469 -1479.
15. Kobayashi K, Yamanaka Y, Iwazaki N, Nakajo I, Hosokawa M, Negishi M, and Chiba K (2005) Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos 33:924-929.
16. Kocarek TA, Dahn MS, Cai H, Strom SC, and Mercer-Haines NA (2002) Regulation of CYP2B6 and CYP3A4 expression by hydroxymethylglutaryl coenzyme A reductase inhibitors in primary cultured human hepatocytes. Drug Metab Dispos 30:1400-1405.
17. Koh KK, Quon MJ, Rosenson RS, Chung WJ, and Han SH (2008) Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. Int J Cardiol 124: 149 -159.
18. Korosec T, Acimovic J, Seliskar M, Kocjan D, Tacer KF, Rozman D, and Urleb U (2008) Novel cholesterol biosynthesis inhibitors targeting human lanosterol 14α-demethylase (CYP51). Bioorg Med Chem 16:209-221.
19. LaRosa JC (2007) Low-density lipoprotein cholesterol reduction: the end is more important than the means. Am J Cardiol 100:240-242.
20. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
21. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz J, Hamilton G, Rizzo C, Jolley S, Gilbert D, et al. (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795-804.
22. Maas R and Böger RH (2003) Old and new cardiovascular risk factors: from unresolved issues to new opportunities. Atheroscler Suppl 4:5-17.
23. Martin JH and Krum H (2007) Statins and clinical outcomes in heart failure. Clin Sci 113:119-127.
24. Miners JO and Birkett DJ (1996) Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods Enzymol 272:139-145.
25. Muscari A, Puddu GM, and Puddu P (2002) Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology 97:115-121.
26. Neuvonen PJ, Niemi M, and Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565-581.
27. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, and Tsutsui M (1996) Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26:681-693.
28. Pascussi JM, Busson-Le Coniat M, Maurel P, and Vilarem M-J (2003a) Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: identification of a distal glucocorticoid response element. Mol Endocrinol 17:42-55.
29. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, and Vilarem MJ (2003b) The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 1619:243-253.
30. Rallidis LS, Lekakis J, and Kremastinos DT (2007) Current questions regarding the use of statins in patients with coronary heart disease. Int J Cardiol 122:188-194.
31. Salsali M, Holt A, and Baker GB (2004) Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol 24:63-76.
32. Sanossian N and Ovbiagele B (2008) Drug insight: translating evidence on statin therapy into clinical benefits. Nat Clin Pract Neurol 4:43-49.
33. Schachter M (2004) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117-125.
34. Shitara Y and Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71-105.
35. Sica DA and Gehr TW (2002) Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol 11:48-55.
36. Srivastava PK, Yun CH, Beaune PH, Ged C, and Guengerich FP (1991) Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol 40:69-79.
37. Strömstedt M, Rozman D, and Waterman MR (1996) The ubiquitously expressed human CYP51 encodes lanosterol 14 α-demethylase, a cytochrome P450 whose expression is regulated by oxysterols. Arch Biochem Biophys 329:73-81.
38. Tiwari A, Bansal V, Chugh A, and Mookhtiar K (2006) Statins and myotoxicity: a therapeutic limitation. Expert Opin Drug Saf 5:651-666.
39. van der Hoeven TA and Coon MJ (1974) Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 249:6302-6310.
40. Wilkening S, Stahl F, and Bader A (2003) Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties. Drug Metab Dispos 31:1035-1042.
41. Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, and Tucker GT (2003) Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 56:433-440.